<SEC-DOCUMENT>0001571049-17-001541.txt : 20170223
<SEC-HEADER>0001571049-17-001541.hdr.sgml : 20170223
<ACCEPTANCE-DATETIME>20170223071029
ACCESSION NUMBER:		0001571049-17-001541
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20170223
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170223
DATE AS OF CHANGE:		20170223

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50626
		FILM NUMBER:		17630718

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>t1700557_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Washington,
D.C. 20549 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 50%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>FORM 8-K </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 50%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>CURRENT REPORT
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Pursuant to
Section 13 or 15(d) </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>of the Securities
Exchange Act of 1934 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Date of Report
(Date of earliest event reported): February 23, 2017</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 50%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 24pt"><B>CYCLACEL PHARMACEUTICALS,
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>(Exact name of registrant as specified in
its charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 50%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>0-50626</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>91-1707622</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt"><B>(State or other jurisdiction</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt"><B>(Commission File Number)</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt"><B>(IRS Employer</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt"><B>of incorporation)</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt"><B>Identification No.)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>200 Connell Drive,
Suite 1500</B><BR>
<B>Berkeley Heights, NJ 07922</B><BR>
<FONT STYLE="font-size: 8pt"><B>(Address of principal executive offices and zip code) </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Registrant&rsquo;s telephone number, including
area code: (908) 517-7330</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>(Former Name or Former Address, if Changed
Since Last Report)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 50%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see </I>General Instruction
A.2. below): </B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD><FONT STYLE="font-size: 10pt"><B>Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD><FONT STYLE="font-size: 10pt"><B>Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD><FONT STYLE="font-size: 10pt"><B>Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD><FONT STYLE="font-size: 10pt"><B>Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 8.01 Other Events.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; background-color: white">On February 23, 2017,
Cyclacel Pharmaceuticals, Inc. issued a press release announcing top-line results from its pivotal Phase 3 SEAMLESS study in elderly
patients aged 70 years or older with newly diagnosed acute myeloid leukemia (AML), who are not candidates for or have refused intensive
induction chemotherapy. A copy of the press release is attached as Exhibit&nbsp;99.1 to this Current Report on Form 8-K, and the
information contained therein is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><B>Item&nbsp;9.01 Financial Statements
and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; background-color: white">(d)&nbsp;Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 15%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 8pt"><B>Exhibit</B><BR>
    <B>Number</B>&nbsp;</FONT></TD>
    <TD STYLE="width: 2%; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 83%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 8pt"><B>Description</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Press release, dated February 23, 2017</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>CYCLACEL PHARMACEUTICALS, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 6%"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="width: 44%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Paul McBarron</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Paul McBarron</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Executive Vice President&mdash;Finance, </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Financial Officer and Chief Operating Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date: February 23, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="width: 15%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 8pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="width: 83%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 8pt"><B>Description</B></FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Press release, dated February 23, 2017</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>t1700557_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 11pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font: 12pt Times New Roman, Times, Serif; text-align: left"><IMG SRC="t1700557_ex99-1p1.jpg"></TD>
    <TD STYLE="width: 1%; font: 12pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 49%; font: 12pt Times New Roman, Times, Serif; text-align: right; vertical-align: middle"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Cyclacel &nbsp;Pharmaceuticals, Inc.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><IMG SRC="t1700557_ex99-1p2.jpg"></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>CYCLACEL
ANNOUNCES TOP-LINE RESULTS FROM PIVOTAL PHASE 3 SEAMLESS study </B></FONT></P>

<P STYLE="font: 12pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>IN
elderly patients with Acute myeloid leukemia</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><I>- Study did not reach statistically
significant improvement in the primary endpoint of overall survival - </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><I>- Improvement in secondary
endpoint of complete remission rate for the experimental arm -</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><I>- Conference call scheduled
today at 9:00 AM Eastern Time -</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>BERKELEY HEIGHTS, NJ, February 23,
2017</B> &mdash; Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) (&quot;Cyclacel&quot; or the &quot;Company&quot;),
a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of
cancer and other serious disorders, today reported top-line results from the pivotal Phase 3 SEAMLESS study in elderly patients
aged 70 years or older with newly diagnosed acute myeloid leukemia (AML), who are not candidates for or have refused intensive
induction chemotherapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The trial did not meet its primary endpoint
of demonstrating statistically significant improvement in overall survival (OS) for the experimental arm versus an active control.&nbsp;
An improved rate of complete remission (CR), a secondary endpoint, was observed in patients who had discontinued therapy at the
time of analysis. Other endpoints and safety were similar between the arms. In the stratified subgroup of patients with low baseline
peripheral white blood cell count, comprising approximately two-thirds of the study&rsquo;s population, an improvement in OS was
observed for the experimental arm. The opposite was true for patients with high white blood cell count. Full results from the SEAMLESS
study will be submitted for presentation at an upcoming medical conference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&ldquo;The results of the SEAMLESS Phase
3 study demonstrate that sapacitabine is active and safe in elderly AML patients,&rdquo; said Hagop Kantarjian M.D., Professor
and Chair, Department of Leukemia, The University of Texas MD Anderson Cancer Center, and chair of the SEAMLESS study. &ldquo;Although
the experimental arm of alternating decitabine-sapacitabine did not reach statistically significant superiority in overall survival,
it is remarkable that an improvement in complete remission rate was observed. Additional analysis of stratified and exploratory
subgroups is warranted to identify patients who are most likely to benefit from treatment with the experimental arm.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">&quot;We
are disappointed not to have reached the primary endpoint of SEAMLESS. Nevertheless, the improvement in CR rate and similar safety
profile are encouraging. We plan to discuss the data with European and US regulatory authorities once subgroup analyses are completed
over the next few months and will report our further plans as they develop. We are grateful to the clinical investigators, and
especially the patients and their families, for their contributions to this large study,&rdquo; said Spiro Rombotis, President
and Chief Executive Officer of Cyclacel. &ldquo;In parallel with data analysis and regulatory discussions, we will reevaluate our
continued investment in sapacitabine in hematological malignancies. Our clinical development strategy in oncology will now concentrate
on our two ongoing, clinical programs in DNA damage response and transcriptional regulation, which include our area of historical
expertise in CDK inhibitors. These programs target biomarker-selected patients, such as those with BRCA mutations or resistance
to existing cancer therapies. Our cash resources are projected to fund these activities and operations through the end of 2018.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#254;</FONT>
<FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">200 Connell Drive, Suite 1500, Berkeley Heights, NJ 07922,
USA Tel +1 908 517 7330 Fax +1 866 271 3466</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT>
<FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">1 James Lindsay Place, Dundee, DD1 5JJ, UK Tel +44 1382
206 062 Fax +44 1382 206 067</FONT></P>

<P STYLE="font: 7pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><U>www.cyclacel.com</U> &ndash; <U>info@cyclacel.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Clinical Development Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">For the past few years the Company has
been progressing clinical investigation of two programs in parallel with the SEAMLESS study based on promising scientific and preclinical
data. The DNA damage response program is evaluating an orally-administered, sequential regimen of sapacitabine and seliciclib,
a CDK2/9 inhibitor, in patients with BRCA positive, advanced solid cancers. The transcriptional regulation program is evaluating
CYC065, a CDK2/9 inhibitor, in patients with advanced cancers with emphasis on downregulation of the Mcl-1 biomarker.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>DNA Damage Response Program</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Phase 1 data from this program in 67 patients
with various advanced cancers were reported at an oral presentation during the 2016 American Society of Clinical Oncology (ASCO)
Annual Meeting. Antitumor activity with durable clinical responses was demonstrated in a subgroup of 45 patients with breast, ovarian
and pancreatic cancers who tested positive for BRCA mutations. A cohort of breast cancer patients who carry BRCA mutations is being
enrolled as an expansion of this study. A further cohort is in preparation which will evaluate alternative dosing schedules and
collect more data in BRCA positive patients with solid tumors other than breast cancer. The DNA Damage Response program is benefiting
from the historical experience with sapacitabine in hematological malignancies, understanding of its mechanism of action and sizable
patient safety database.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Transcriptional Regulation Program</B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Cyclacel&rsquo;s second generation CDK2/9
inhibitor, CYC065, is being evaluated in an ongoing, first-in-human, Phase 1 trial in patients with advanced solid tumors. In addition
to determining safety and recommended dosing for Phase 2, the study aims to investigate CYC065&rsquo;s effects on the Mcl-1 biomarker,
which is implicated in the evolution of resistance in cancer. The study has reached the seventh dose escalation level without observations
of serious toxicity. Evidence of target engagement of prolonged Mcl-1 suppression in peripheral blood cells was observed in patient
samples from the study, as well as decreases in kinase substrate phosphorylation and increases in PARP cleavage, which were consistent
with the Company&rsquo;s preclinical data.</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Similar to palbociclib, the first CDK
inhibitor approved by FDA in 2015, CYC065 may be most useful as a therapy for patients with both liquid and solid tumors in combination
with other anticancer agents, including Bcl-2 antagonists, such as venetoclax, or HER2 inhibitors, such as trastuzumab.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Conference Call and Webcast Information:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Cyclacel will hold a conference call on
February 23, 2017 at 9:00 a.m. Eastern Time to discuss the Company&rsquo;s plans with regard to SEAMLESS. Conference call and webcast
details are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">US/Canada call: (877) 493-9121/ international
call: (973) 582-2750</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">US/Canada archive: (800) 585-8367 / international
archive: (404) 537-3406</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Code for live and archived conference
call is: 77162157</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">For the live and archived webcast, please
visit the Corporate Presentations and Events page on the Cyclacel website at www.cyclacel.com. The webcast will be archived for
90 days and the audio replay for 7 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 12pt Calibri (Body)"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>About SEAMLESS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The Phase 3, randomized trial compared
an investigational arm of oral sapacitabine administered in alternating cycles with intravenous decitabine compared with an active
control arm of intravenous decitabine administered alone. The trial was conducted at 110 US and EU sites and randomized 491 patients,
over an approximately three year period. Stratification factors at randomization were antecedent hematologic disorders, baseline
peripheral white blood cells and baseline bone marrow blasts. In December 2014, the study&rsquo;s monitoring committee determined
after an interim analysis that the futility boundary was crossed. In accordance with the committee&rsquo;s recommendations, the
Company continued to follow up enrolled patients to maturity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0"><B>About Sapacitabine </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Sapacitabine (CYC682), an orally-available
nucleoside analogue, acts through a novel DNA single-strand breaking mechanism, leading to production of DNA double strand breaks
(DSBs) and/or checkpoint activation. Unrepaired DSBs cause cell death. Repair of sapacitabine-induced DSBs is dependent on the
homologous recombination repair (HRR) pathway. Both sapacitabine and its major metabolite, CNDAC, have demonstrated potent anti-tumor
activity in preclinical studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">In addition to the SEAMLESS Phase 3 study
in elderly patients with AML who were unfit or refused intensive induction chemotherapy, other Phase 2 studies evaluated sapacitabine
in patients with myelodysplastic syndromes (MDS), cutaneous T cell lymphoma (CTCL) and non-small cell lung cancer (NSCLC). The
US FDA and the European Medicines Agency have designated sapacitabine as an orphan drug for the treatment of both AML and MDS.
Sapacitabine is part of Cyclacel's pipeline of small molecule drugs designed to target and stop uncontrolled cell division.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>About Cyclacel Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; background-color: white">Cyclacel Pharmaceuticals
is a clinical-stage biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response biology to
develop innovative, targeted medicines for cancer and other proliferative diseases. Cyclacel's DNA damage response program is
evaluating a sequential regimen of sapacitabine and seliciclib, a CDK inhibitor, in patients with BRCA positive, advanced solid
cancers. The transcriptional regulation program is evaluating CYC065, a CDK inhibitor, in patients with advanced cancers. Cyclacel
is analyzing stratified and exploratory subgroups from a Phase 3 study of sapacitabine in elderly patients with AML. Cyclacel's
strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a pipeline of novel
drug candidates. For additional information, please visit <U>www.cyclacel.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Forward-looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">This news release contains certain forward-looking
statements that involve risks and uncertainties that could cause actual results to be materially different from historical results
or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements
regarding, among other things, the efficacy, safety and intended utilization of Cyclacel's product candidates, the conduct and
results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding
partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that
appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical
trials,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 12pt Calibri (Body)"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">trials may have difficulty enrolling,
Cyclacel may not obtain approval to market its product candidates, the risks associated with reliance on outside financing to meet
capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development
and commercialization of product candidates. You are urged to consider statements that include the words &quot;may,&quot; &quot;will,&quot;
&quot;would,&quot; &quot;could,&quot; &quot;should,&quot; &quot;believes,&quot; &quot;estimates,&quot; &quot;projects,&quot; &quot;potential,&quot;
&quot;expects,&quot; &quot;plans,&quot; &quot;anticipates,&quot; &quot;intends,&quot; &quot;continues,&quot; &quot;forecast,&quot;
&quot;designed,&quot; &quot;goal,&quot; or the negative of those words or other comparable words to be uncertain and forward-looking.
For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report
on Form 10-K and other periodic and other filings we file with the Securities and Exchange Commission and are available at www.sec.gov.
Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking
statements, whether as a result of new information, future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Contacts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 23%"><FONT STYLE="font-family: Calibri, Helvetica, Sans-Serif; font-size: 11pt">Company:</FONT></TD>
    <TD STYLE="width: 77%"><FONT STYLE="font-family: Calibri, Helvetica, Sans-Serif; font-size: 11pt">Paul McBarron, (908) 517-7330, <U>pmcbarron@cyclacel.com</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Calibri, Helvetica, Sans-Serif; font-size: 11pt">Investor Relations:</FONT></TD>
    <TD><FONT STYLE="font-family: Calibri, Helvetica, Sans-Serif; font-size: 11pt">Russo Partners LLC, Alexander Fudukidis, (646) 942-5632, <U>alex.fudukidis@russopartnersllc.com</U></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">&copy;
Copyright 2017 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel&reg; are trademarks of Cyclacel
Pharmaceuticals, Inc. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 12pt Calibri (Body)"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>t1700557_ex99-1p1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 t1700557_ex99-1p1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 1 "U P$1  (1 0,1 ?_$ *H  0 " P$  P$
M       ("08'"@4" P0! 0$  04! 0$             !@,$!0<("0$"$
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M )E&Y"AW#Q;W/[&<O[9L<W(49O&RUERH0=*W\!,G5H6/[;H3T5R>E>BO9?\
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MR09,*J0ZGK9@0?B*IYOXV87'0=Q[-[MN/'=X5K^B\TN9MLZD@O#DX>0T@9&
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MKFQ-8GC7%LA^,\E[(0R+!R38=T.X;0[^'MYL@[CMDP^,<66LN)-I%E$96PN
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33BE.*4XI3BE.*4XI3BE.*5__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>t1700557_ex99-1p2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 t1700557_ex99-1p2.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ %P)- P$1  (1 0,1 ?_$ &\  0 #  (" P
M       '" D%!@,$ 0(* 0$                     $   !0,# P0" @$%
M       ! @,$!0 &!],75Q$2ER$3% @Q(D$5(V$R)!8)$0$
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M4K]R(FW;C@LDWI;*V(VSD]IXW?RB,L+\)21(E*_'CY6+'XK,IA]X_?U !+U
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M (#UH)$QU8-OXOLBV[ M9%9&!MB.3CF .5??=*% YUEG+I;M+[CETY5.H<0
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GV:B@@X:MQ0-BVY"NE1=IO%2JH("CWJMT 9""IP]$S*)@/J<M!__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
